A Multidisciplinary Approach to the Diagnosis and Treatment of Gastrointestinal Stromal Tumor

被引:24
作者
Mullady, Daniel K. [1 ]
Tan, Benjamin R. [1 ]
机构
[1] Washington Univ, Sch Med, Div Oncol, St Louis, MO 63110 USA
关键词
gastrointestinal stromal tumor; GIST; imatinib mesylate; diagnosis; multidisciplinary; FINE-NEEDLE-ASPIRATION; RECEPTOR TYROSINE KINASE; IMATINIB MESYLATE; LAPAROSCOPIC RESECTION; PROGNOSTIC-FACTORS; ADJUVANT IMATINIB; PDGFRA MUTATIONS; KIT ACTIVATION; RISK CRITERIA; SOFT-TISSUE;
D O I
10.1097/MCG.0b013e3182936c87
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Management of patients with gastrointestinal stromal tumor (GIST) typically involves a combination of surgical, pathologic, and pharmacologic interventions. Gastroenterologists are often the first specialists to encounter patients presenting with GIST and are therefore responsible for facilitating early intervention strategies. Although patients with gastric or small-bowel GISTs typically present with symptoms, a diagnosis of GIST should be considered whenever a submucosal lesion is seen endoscopically. Visualization by standard endoscopy often can determine tumor location and size, although endoscopic ultrasound (EUS) is the most accurate imaging technique for submucosal lesions. Biopsy techniques that yield sufficient tumor samples for diagnostic studies, such as EUS-guided fine needle aspiration, are essential, although other approaches such as EUS-guided core needle biopsy may increase diagnostic yield for subepithelial lesions. Pathology assessment should include immunohistochemical staining for KIT and possibly DOG1 expression, and mutational analysis can have prognostic and predictive value for certain patients. R0 resection is the goal for patients with localized or potentially resectable tumors, which often can be accomplished by laparoscopic resection, even for larger tumors. Medical oncologists play a key role in assessing risk of recurrence after resection and optimizing tyrosine kinase inhibitor therapy in the adjuvant or metastatic setting. Cytoreductive surgery may have value for patients with recurrent or metastatic GIST who exhibit stable disease or respond to tyrosine kinase inhibitor therapy. A coordinated multidisciplinary approach over the course of the disease will serve to enhance communication among GIST team members, reduce risk of progression, and optimize outcomes.
引用
收藏
页码:578 / 585
页数:8
相关论文
共 70 条
  • [1] V600E BRAF mutations are alternative early molecular events in a subset of KIT/PDGFRA wild-type gastrointestinal stromal tumours
    Agaimy, A.
    Terracciano, L. M.
    Dirnhofer, S.
    Tornillo, L.
    Foerster, A.
    Hartmann, A.
    Bihl, M. P.
    [J]. JOURNAL OF CLINICAL PATHOLOGY, 2009, 62 (07) : 613 - 616
  • [2] The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis
    Ando, N
    Goto, H
    Niwa, Y
    Hirooka, Y
    Ohmiya, N
    Nagasaka, T
    Hayakawa, T
    [J]. GASTROINTESTINAL ENDOSCOPY, 2002, 55 (01) : 37 - 43
  • [3] [Anonymous], National Comprehensive Cancer Network Compendium
  • [4] Epidemiology of GIST
    Blanke, C
    Eisenberg, BL
    Heinrich, M
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2005, 100 (10) : 2366 - 2366
  • [5] Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Blanke, Charles D.
    Rankin, Cathryn
    Demetri, George D.
    Ryan, Christopher W.
    von Mehren, Margaret
    Benjamin, Robert S.
    Raymond, A. Kevin
    Bramwell, Vivien H. C.
    Baker, Laurence H.
    Maki, Robert G.
    Tanaka, Michael
    Hecht, J. Randolph
    Heinrich, Michael C.
    Fletcher, Christopher D. M.
    Crowley, John J.
    Borden, Ernest C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (04) : 626 - 632
  • [6] Laparoscopic treatment of gastric GIST: Report of 21 cases and literature's review
    Catena, Fausto
    Di Battista, Monica
    Fusaroli, Pietro
    Ansaloni, Luca
    Di Scioscio, Valerio
    Santini, Donatella
    Pantaleo, Maria
    Biasco, Guido
    Caletti, Giancarlo
    Pinna, Antonio
    [J]. JOURNAL OF GASTROINTESTINAL SURGERY, 2008, 12 (03) : 561 - 568
  • [7] Endosonographic differentiation of benign and malignant stromal cell tumors
    Chak, A
    Canto, MI
    Rosch, T
    Dittler, HJ
    Hawes, RH
    Tio, TL
    Lightdale, CJ
    Boyce, HW
    Scheiman, J
    Carpenter, SL
    VanDam, J
    Kochman, ML
    Sivak, MV
    [J]. GASTROINTESTINAL ENDOSCOPY, 1997, 45 (06) : 468 - 473
  • [8] Small and microscopically detected gastrointestinal stromal tumours: an overview
    Chetty, Runjan
    [J]. PATHOLOGY, 2008, 40 (01) : 9 - 12
  • [9] Molecular pathobiology of gastrointestinal stromal sarcomas
    Corless, Christopher L.
    Heinrich, Michael C.
    [J]. ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE, 2008, 3 : 557 - 586
  • [10] PDGFRA mutations in gastrointestinal stromal tumors: Frequency, spectrum and in vitro sensitivity to imatinib
    Corless, CL
    Schroeder, A
    Griffith, D
    Town, A
    McGreevey, L
    Harrell, P
    Shiraga, S
    Bainbridge, T
    Morich, J
    Heinrich, MC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) : 5357 - 5364